Michael Mauro

22PUBLICATIONS
82CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCharacterisation of biological macromolecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Jul 24, 2026
Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial.

|Jul 16, 2026
Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.

|Dec 02, 2025
How I treat advanced phases of CML.

Michael J Mauro

|Oct 07, 2025
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.

Ehab Atallah, Michael S Broder, Onyee Chan

|Jul 11, 2025
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.

Jane F Apperley, Dragana Milojkovic, Nicholas C P Cross

|May 07, 2025
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.

Michael J Mauro, Yosuke Minami, Andreas Hochhaus

Pageof 4

Frequent Collaborators

15 joint publications

Jorge E Cortes

11 joint publications

Andreas Hochhaus

10 joint publications

Jane F Apperley

7 joint publications

Daniel J DeAngelo